Cytokine Release Syndrome clinical trials at UCSF
1 research study open to eligible people
Cytokine release syndrome is when the immune system releases many inflammatory signals that can make people very sick. UCSF is running clinical trials that combine immune therapies with chemotherapy for relapsed blood cancers. UCSF is tracking symptoms, lab tests, and drug levels to describe the syndrome.
Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
open to eligible people ages 18 years and up
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with relapsed or refractory (R/R) aggressive B-cell Non-Hodgkin's lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
San Francisco, California and other locations
Last updated: